Screening for Neuroblastoma

  • William G. Woods
Part of the Pediatric Oncology book series (PEDIATRICO)


Clin Oncol Childhood Cancer Standardize Mortality Ratio Mass Screening Standardize Incidence Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ater JL, Gardner KL, Foxhall LE et al. (1998) Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening. Cancer 82:1593–1602CrossRefPubMedGoogle Scholar
  2. Bell S, Parker L, Cole M et al. (1994) Screening infants for neuroblastoma: the parents' perspective in false-positive cases. Pediatr Hematol Oncol 11:157–163PubMedGoogle Scholar
  3. Bergeron C, Tafese T, Kerbl R et al. (1998) European experience with screening for neuroblastoma before the age of 12 months. Med Pediatr Oncol 31:442–449CrossRefGoogle Scholar
  4. Bernstein M, Leclerc J, Bunin G et al. (1992) A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 10:323–329PubMedGoogle Scholar
  5. Bessho F, Hashizume K, Nakajo T, Kamoshita S (1991) Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 119:237–241PubMedGoogle Scholar
  6. Brodeur G, Ambros P, Favrot M (1998) Biological aspects of neuroblastoma screening. Med Pediatr Oncol 31:394–400CrossRefGoogle Scholar
  7. Brodeur GM, Look AT, Shimada H et al. (2001) Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncol 36:157–159CrossRefPubMedGoogle Scholar
  8. Brodeur GM, Nakagawara A (1992) Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol-Oncol 14:111–116PubMedGoogle Scholar
  9. Carlsen NLT (1986) Epidemiological investigations on neuroblastomas in Denmark, 1943–1980. Br J Cancer 54:977–988PubMedGoogle Scholar
  10. Craft AW, Dale G, McGill A et al. (1989) Biochemical screening for neuroblastoma in infants: a feasibility study. Med Pediatr Oncol 17:373–378PubMedGoogle Scholar
  11. D'Angio G, Evans A, Koop C (1971) Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1:1046–1049CrossRefPubMedGoogle Scholar
  12. Dobrovoljski G, Kerbl R, Strobl C et al. (2003) False-positive results in neuroblastoma screening: the parents' view. J Pediatr Hem Oncol 25:14–18CrossRefGoogle Scholar
  13. Esteve J, Parker L, Roy P et al. (1995) Is neuroblastoma screening evaluation needed and feasible? Br J Cancer 71:1125–1131PubMedGoogle Scholar
  14. Hinterberger H, Bartholomew RJ (1969) Catecholamines and their acidic metabolites in urine and tumor tissue in neuroblastoma, ganglioneuroma and pheochromocytoma. Clin Chim Acta 26:291–294Google Scholar
  15. Kaneko Y, Kanda N, Maseki N et al. (1990) Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 8:2005–2013PubMedGoogle Scholar
  16. Kerbl R, Urban C, Ladenstein R et al. (1997) Neuroblastoma screening in infants postponed after the sixth month of age: a trial to reduce “overdiagnosis” and to detect cases with unfavourable” biological features. Med Pediatr Oncol 29:1–10PubMedGoogle Scholar
  17. LaBrosse EH (1968) Biochemical diagnosis of neuroblastoma; use of the urine spot test. Proc Am Assoc Cancer Res 9:39Google Scholar
  18. Mason GA, Hart-Mercer J, Miller ES et al. (1957) Adrenaline-secreting neuroblastoma in an infant. Lancet 2:322–325CrossRefGoogle Scholar
  19. Mathieu P, Frappaz D, Chauvin F et al. (1996) A 5-year (1990–1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations. Early Hum Dev 46:177–196CrossRefPubMedGoogle Scholar
  20. Matthay KK, Sather HN, Seeger RC et al. (1989) Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7:236–244PubMedGoogle Scholar
  21. Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
  22. Nishi M, Miyake H, Takeda T et al. (1987) Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 60:433–436PubMedGoogle Scholar
  23. Prorok P, Connor R (1986) Screening for the early detection of cancer. Cancer Invest 4:225–238PubMedGoogle Scholar
  24. Ross JA, Severson RK, Pollock BH et al. (1996) Childhood cancer in the United States: a geographical analysis of cases from the pediatric cooperative clinical trials groups. Cancer 77:201–207CrossRefPubMedGoogle Scholar
  25. Sawada T (1986) Outcome of 25 Neuroblastomas revealed by screening in Japan. Lancet 1:377CrossRefGoogle Scholar
  26. Sawada T, Nakata T, Takasugi N et al. (1984) Mass screening for neuroblastoma in infants in Japan. Lancet 2:271–273CrossRefPubMedGoogle Scholar
  27. Sawada T, Takeda T (2000) Screening for neuroblastoma in infancy in Japan. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 245–264Google Scholar
  28. Sawada T, Todo S, Fujita K et al. (1982) Mass screening of neuroblastoma in infancy. Am J Dis Child 136:710–712PubMedGoogle Scholar
  29. Schilling F, Oberrauch W, Schanz F et al. (1991) Evaluation of a rapid and reliable method for mass screening for neuroblastoma in infants. Prog Clin Biol Res 366:579–583PubMedGoogle Scholar
  30. Schilling F, Spix C, Berthold F et al. (1998) German neuroblastoma screening study at 12 months of age: statistical aspects and preliminary results. Med Pediatr Oncol 31:435–441CrossRefGoogle Scholar
  31. Schilling F, Spix, C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346:1047–1053CrossRefPubMedGoogle Scholar
  32. Scriver C, Gregory D, Bernstein M et al. (1987) Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. Can Med Assoc J 136:952–956Google Scholar
  33. Suita S, Tajiri T, Akazawa K et al. (1998) Mass screening for neuroblastoma at 6 months of age: difficult to justify. J Pediatr Surg 33:1674–1678CrossRefPubMedGoogle Scholar
  34. Tsubono Y, Hisamichi S (2004) A halt to neuroblastoma screening in Japan. N Engl J Med 350:2010CrossRefPubMedGoogle Scholar
  35. Tuchman M, Crippin PJ, Krivit W (1983) Capillary gas chromatographic determination of urinary homovanillic acid and vanillylmandelic acid. Clin Chem 29:828–831PubMedGoogle Scholar
  36. Tuchman M, Robison LL, Maynard RC et al. (1985) Assessment of the diurnal variations in urinary homovanillic acid and vanillylmandelic acid excretion for the diagnosis and follow up of patients with neuroblastoma. Clin Biochem 18:176–179CrossRefPubMedGoogle Scholar
  37. Tuchman M, Ramnaraine ML, Woods WG et al. (1987) Three years of experience with random urinary homovanillic and vanillymandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 79:203–205PubMedGoogle Scholar
  38. Tuchman M, Fisher E, Heisel M, Woods WG (1989) Feasibility study for neonatal neuroblastoma screening in the United States. Med Pediatr Oncol 17:258–264PubMedGoogle Scholar
  39. Tuchman M, Lemieux B, Woods WG (1990) Editorial: screening for neuroblastoma in infants: investigate or implement? Pediatrics 86:791–793PubMedGoogle Scholar
  40. Woods WG, Tuchman M (1987) Neuroblastoma: the case for screening infants in North America. Pediatrics 79:869–873PubMedGoogle Scholar
  41. Woods WG, Lemieux B, Tuchman M (1992) Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 89:114–118PubMedGoogle Scholar
  42. Woods WG, Tuchman M, Robison L et al. (1996) A population-based study of the usefulness of screening for neuroblastoma. Lancet 348:1682–1672CrossRefPubMedGoogle Scholar
  43. Woods WG, Bernstein M, Lemieux B (1999) Commentary: randomized controlled trials in population-based intervention studies are not always feasible. Med Pediatr Oncol 33:360–361CrossRefPubMedGoogle Scholar
  44. Woods WG, Gao R, Shuster J et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041–1046CrossRefPubMedGoogle Scholar
  45. Yamamoto K, Hayashi Y, Hanada R et al. (1995) Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 13:2033–2038PubMedGoogle Scholar
  46. Yamamoto K, Hanada R, Kikuchi A et al. (1998) Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 16:1265–1269PubMedGoogle Scholar
  47. Yamamoto K, Ohta S, Ito E et al. (2002) Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. J Clin Oncol 20:1209–1214CrossRefPubMedGoogle Scholar
  48. Young JL, Ries LG, Silverberg E et al. (1986) Cancer incidence, survival and mortality for children under 15 years of age. Cancer 58:598–602PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • William G. Woods

There are no affiliations available

Personalised recommendations